AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer's disease
MarketScreener,
AB SCIENCE COMMUNICATES RESULTS FROM PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE Paris, December 18, 2020, 8.30a…